Mark S. Berger
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 11
- Hematology top 1%
- Acute Myeloid Leukemia Research 16
- Multiple Myeloma Research and Treatments 7
-
- Radiopharmaceutical Chemistry and Applications 14
- Monoclonal and Polyclonal Antibodies Research 9
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 8
- Cancer Research top 2%
-
- Cancer therapeutics and mechanisms 12
-
- Lung Cancer Treatments and Mutations 8
- Co-authors
- Stephen ChanCharles E. GeyerTadeusz PieńkowskiSteven SteinDavid CameronAgnieszka Jagiełło-GruszfeldCristina OlivaNeville Davidson
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Mark S. Berger
66 papers receiving 6.7k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 4.6k
- Hematology 1.1k
- Radiology, Nuclear Medicine and Imaging 2.1k
- Genetics 736
- Cancer Research 743
Countries citing papers authored by Mark S. Berger
This map shows the geographic impact of Mark S. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Berger more than expected).
Fields of papers citing papers by Mark S. Berger
This network shows the impact of papers produced by Mark S. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Berger. The network helps show where Mark S. Berger may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark S. Berger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2020 | 23 | |
| 3 | 2017 | 2 | |
| 4 | 2017 | 7 | |
| 5 | 2014 | 35 | |
| 6 | 2014 | 41 | |
| 7 | 2014 | 55 | |
| 8 | 2010 | 80 | |
| 9 | 2005 | 322 | |
| 10 | 2003 | 43 | |
| 11 | 2002 | 29 | |
| 12 | 2001 | 270 | |
| 13 | 2001 | 108 | |
| 14 | Preliminary report of an ascending dose study of gemtuzumab ozogamicin (mylotarg™, cma-676) in pediatric patients with acute myeloid leukemia | 2000 | 10 |
| 15 | 1996 | 24 | |
| 16 | 1995 | 8 | |
| 17 | 1993 | 21 | |
| 18 | 1990 | 9 | |
| 19 | Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.breakdown → | 1988 | 507 |
| 20 | Linear-Phase Bandsplitting: Theory and Applications | 1986 | 16 |
About Mark S. Berger
Mark S. Berger is a scholar working on Hematology, Oncology, Radiology, Nuclear Medicine and Imaging, Genetics and Neurology, having authored 68 papers that have together received 6.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (16 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Cancer therapeutics and mechanisms (12 papers), HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Chronic Lymphocytic Leukemia Research (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Multiple Myeloma Research and Treatments (7 papers). The work is most often cited by research in Oncology (4.6k citations), Hematology (1.1k citations), Radiology, Nuclear Medicine and Imaging (2.1k citations), Genetics (736 citations) and Cancer Research (743 citations). Mark S. Berger has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Stephen Chan, Charles E. Geyer, Tadeusz Pieńkowski, Steven Stein, David Cameron, Agnieszka Jagiełło-Gruszfeld, Cristina Oliva, Neville Davidson, Dimosthenis Skarlos and Mario Campone. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Biology of Blood and Marrow Transplantation and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.